首页> 外文OA文献 >Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

【2h】

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

机译：第2阶段试验结果与新型神经喹啉-1受体拮抗剂潜水剂与ondansetron和地塞米松组合用于预防化疗诱导的恶心，癌症患者患者接受中度胰腺化疗的癌症患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. Bandekar; Steven M. Grunberg;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. [J] . Arpornwirat W, Albert I, Hansen V Cancer: A Journal of the American Cancer Society . 2009,第24期

机译：新型神经激肽-1受体拮抗剂casopitant联合恩丹西酮和地塞米松在预防中度致癌化学疗法的癌症患者中预防化疗引起的恶心和呕吐的2期试验结果。
2. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. [J] . Herrstedt J, Apornwirat W, Shaharyar A Journal of Clinical Oncology . 2009,第32期

机译：新型神经激肽-1受体拮抗剂casopitant的III期临床试验，用于预防中度致呕性化疗患者的恶心和呕吐。
3. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. [J] . Grunberg SM, Rolski J, Strausz J The lancet oncology . 2009,第6期

机译：甲磺酸神经舒张素1（NK1）受体拮抗剂casopitant甲磺酸盐在预防以顺铂为基础的高度致呕性化疗患者化疗引起的恶心和呕吐方面的功效和安全性：一项随机，双盲，安慰剂对照试验。
4. The Effect of Acupressure Wristbands Toward Acute Nausea and Vomiting on Post-Chemotherapy Cervix Cancer Patient in Prof. Dr. Margono Soekarjo Hospital Purwokerto [C] . Efita Yulianasari, Siti Haniyah, Indri Heri Susanti International Conference on Community Health . 2020

机译：Acu压抑腕带对急性恶心的影响，呕吐在化疗后宫颈癌患者Margono Soekarjo医院Purwokerto博士
5. Aprepitant for the Prevention of Acute Chemotherapy-induced Nausea and Vomiting in Children: Overcoming Barriers [D] . Patel, Priya 2018

机译：预防急性化疗引起的儿童恶心和呕吐的阿瑞品：克服障碍
6. Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy [O] . Ralph Boccia, Erin O’Boyle, William Cooper 2016

机译：APF530与帕洛诺司琼在预防中度或高度致呕性化疗的部分乳腺癌患者中化疗引起的恶心和呕吐的预防性随机III期试验
7. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial [O] . Amber B. Clemmons, Julianne Orr, Benjamin Andrick, 2018

机译：随机，安慰剂对照，FosapRepitant，Ondansetron，Dexamethasone（喜欢的）与Fond Plus Olanzapine（FONE-O）进行血液学恶性肿瘤患者的血液学恶性肿瘤患者呕吐，ondansetron，ondansetron（Fond-O）的试验。接受高均匀化疗和造血细胞移植的血液学恶性肿瘤患者方案：FOND-O试验

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅